Lyme Disease – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026
Lyme Disease Emerging Therapy and TPP Insights Thelansis’s “Lyme Disease Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Lyme Disease Overview Lyme disease is a tick-borne bacterial infection that, when caught early, is generally treated successfully with a short course of oral antibiotics, making acute care for typical presentations a largely solved clinical problem. The more persistent challenge lies at two edges of that success: a meaningful minority of patients continue to experience fatigue, joint pain, or cognitive symptoms even after standard antibiotic treatment; a poorly understood condition that has resisted consensus diagnosis and effective therapy, and prevention has lacked a viable tool since an earlier vaccine was withdraw...